Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

The trial contains standard assessments of safety, tolerability and pharmacokinetics. The clinical endpoints reflect change in symptom frequency and severity and the data should be available later in 2008.

GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial in patients with major depressive disorder. Enrollment of approximately 150 subjects is anticipated in this 6-week randomized, double-blind, placebo-controlled trial.

In addition to the two compounds listed above, GSK has also successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression.

Urocortin 2 for Congestive Heart Failure (CHF) Continues Preclinical Evaluation

Initiation of longer term (up to 72 hours in duration) Phase II clinical trials of urocortin 2 are awaiting additional preclinical data. The Company has identified five preclinical studies necessary to support the longer period of infusion in the clinical program. Two of these five preclinical studies were successfully completed by July 2008. The two completed studies were non- GLP toxicology and safety assessment studies over 14 days of continuous infusion in distinct species models. The favorable results of these studies now await confirmation in the GLP preclinical studies anticipated later in 2008.

Indiplon Update

The Company met with the FDA in July for an end of review meeting related to the December 12, 2007 approvable letter for indiplon capsules. The FDA meeting focused on the three additional requirements outlined in the approvable letter. After exchange of correspondence regarding meeting minutes, the Company is awaiting the FDA's final version of these minutes to determine the next course of action related to indiplon capsules.

Conference Call and Webcast Today at 5:00 p.m. Eastern Daylight Time

Neurocrine will hold a live conference call and webcast tod
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech ... compounds to safely regress atherosclerotic plaque and improve ... partner, CardioNova, has accomplished first dosing of subjects ... lead compound, AHRO-001.  This Phase 1b trial will ... safety trial completed in February 2014, in which ...
(Date:7/30/2014)... 30, 2014 NCERC at Southern ... present his findings on corn stover pretreatment methods ... week in Washington, D.C. , “Arun’s selection ... is a testament to the success of our ... “Thanks to the foresight and vision of SIUE ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... 1, 2012  Receptos Inc. today announced that the company is ... Health Care Conference at noon EST on Wednesday, March 7, ... Faheem Hasnain, president and chief executive officer, will provide an ... development programs. "This is an exciting time ...
... 2012 Unigene Laboratories, Inc. (OTCBB: UGNE), a leader ... therapeutics announced today that the Company,s senior management team ... on Thursday, March 8, 2012 at 11 a.m. ET ... Interested participants and investors may access ...
... Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., ... Thursday, March 1 at 10:35 AM EST. The conference is ... The IN360 is the newest iteration of the ... medical device technology forum and networking meeting. The foundation of ...
Cached Biology Technology:Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference 2
(Date:7/30/2014)... , July 30, 2014 ... Global Government Biometric Systems Market 2014-2024   Business ... The Global Biometric Systems Market 2014-2024" offers the ... market over the next ten years, alongside potential ... market size forecasts. To view the ...
(Date:7/30/2014)... an across-the-board increase in Impact Factors for its ... Citation Reports (Thomson Reuters, 2014) show that ... Essays in Biochemistry , Biochemical Society Transactions ... increases in their Impact Factors. The journals are ... Portland Press Limited. , 2014 Impact Factors (2013 ...
(Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
Breaking Biology News(10 mins):Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2Decades-old amber collection offers new views of a lost world 2
... On a popular children's game participants stand as close ... coaxing cells to be very, very close without actually ... challenges for cell biologists. , Now MIT researchers led ... computer science at the Harvard-MIT Division of Health Sciences ...
... Researchers at Mount Sinai School of Medicine have just ... of the microdomains of leukocytes or white blood cells. ... cells in which receptors and signaling molecules accumulate during ... to view white blood cell subsets and their forming ...
... sugars, a technique developed by University of Michigan analytical ... diagnosis and treatment options. , A growing body of ... to proteins on cancer cell surfaces as accomplices in ... keen to characterize these glycans, but traditional analytical methods ...
Cached Biology News:MIT device draws cells close -- but not too close -- together 2MIT device draws cells close -- but not too close -- together 3New imaging technique tracks traffic patterns of white blood cells 2A sweet step toward new cancer therapies 2
Mouse monoclonal antibody raised against a partial recombinant WDR5. NCBI Entrez Gene ID = WDR5...
... kit is a sample preparation kit for ... removal of detergents, phenolic compounds, salts, and ... dilute samples. The kit procedure involves a ... tissue or cells, plant leaves, E. coli, ...
... is intended for first-time users of the PROTEAN ... includes a protein sample and reagents sufficient to ... 17 cm, ten 11 cm, or sixteen 7 ... precast SDS-PAGE gels and gels stains are not ...
... Immunogen : Fusion protein ... 474-970 of human Mi-2 Formulation: ... NaCl, 0.035% sodium azide, containing ... evaluated by immunoblot on Hela ...
Biology Products: